Abstract
Melphalan in combination with glucocorticoid steroids has been an important first-line treatment option for multiple myeloma (MM) for over 40 years, but response rates have been only 50-60%, with less than 5% complete remissions (CRs). More intensive combinations of chemotherapy such as vincristine, Adriamycin and Dexamethasone (Dex) (VAD) improved objective response rates to 40%-70%, with 10-17% complete responses, but overall survival (OS) was not significantly improved. High-dose therapy with autologous hematopoietic stem cell transplantation (AHCT) has improved OS by approximately 12 months in three prospective randomized trials, but is not available to many patients. More recently, novel therapies thalidomide, the immunomodulatory thalidomide analogue Revlimid, and the proteasome inhibitor bortezomib have demonstrated significant activity to overcome drug resistance in patients with relapsed and refractory MM. Early results indicate that these novel therapeutics have even more impressive activity in combination with conventional therapies prior to AHCT, as well as following AHCT. Furthermore, these novel therapies should be more widely available to most patients with MM.
Keywords: cyclophosphamide, Erythropoietin, Tandem Transplantation, Allografting, thalidomide, Proteasome Inhibitors
Current Cancer Therapy Reviews
Title: Treatment Strategies for Multiple Myeloma in the Age of Novel Therapies
Volume: 2 Issue: 2
Author(s): Laurence Catley and Kenneth C. Anderson
Affiliation:
Keywords: cyclophosphamide, Erythropoietin, Tandem Transplantation, Allografting, thalidomide, Proteasome Inhibitors
Abstract: Melphalan in combination with glucocorticoid steroids has been an important first-line treatment option for multiple myeloma (MM) for over 40 years, but response rates have been only 50-60%, with less than 5% complete remissions (CRs). More intensive combinations of chemotherapy such as vincristine, Adriamycin and Dexamethasone (Dex) (VAD) improved objective response rates to 40%-70%, with 10-17% complete responses, but overall survival (OS) was not significantly improved. High-dose therapy with autologous hematopoietic stem cell transplantation (AHCT) has improved OS by approximately 12 months in three prospective randomized trials, but is not available to many patients. More recently, novel therapies thalidomide, the immunomodulatory thalidomide analogue Revlimid, and the proteasome inhibitor bortezomib have demonstrated significant activity to overcome drug resistance in patients with relapsed and refractory MM. Early results indicate that these novel therapeutics have even more impressive activity in combination with conventional therapies prior to AHCT, as well as following AHCT. Furthermore, these novel therapies should be more widely available to most patients with MM.
Export Options
About this article
Cite this article as:
Catley Laurence and Anderson C. Kenneth, Treatment Strategies for Multiple Myeloma in the Age of Novel Therapies, Current Cancer Therapy Reviews 2006; 2 (2) . https://dx.doi.org/10.2174/157339406776872807
DOI https://dx.doi.org/10.2174/157339406776872807 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular Toxicity of Chemotherapeutic Agents
Current Vascular Pharmacology Snake Venom Peptides and Low Mass Proteins: Molecular Tools and Therapeutic Agents
Current Medicinal Chemistry Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design An Efficient Multiple Kernel Support Vector Regression Model for Assessing Dry Weight of Hemodialysis Patients
Current Bioinformatics Development of Calorie Restriction Mimetics as Therapeutics for Obesity, Diabetes, Inflammatory and Neurodegenerative Diseases
Current Genomics Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment
Current Alzheimer Research The Effects of Drugs Used in Anaesthesia on Platelet Membrane Receptors and on Platelet Function
Medicinal Chemistry Reviews - Online (Discontinued) Role of CD14 in Host Response to Infection
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Radioprotective Effects of Plants from the Lamiaceae Family
Anti-Cancer Agents in Medicinal Chemistry Characterization of a Novel ADPase in Bothrops jararaca Snake Venom Involved in Nucleotide Hydrolysis
Protein & Peptide Letters Essential Oils and Alcohol Extracts of Northwest Tunisia <i>M. communis</i> and <i>M. spicata</i>: Phytocompounds, Antioxidant and Antibacterial Activities
Current Bioactive Compounds Community-Acquired Pneumonia and Outcome: The Importance of Genetics
Current Respiratory Medicine Reviews Toll-Like Receptors and their Role in Renal Pathologies
Inflammation & Allergy - Drug Targets (Discontinued) Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors
Current Diabetes Reviews Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology Discovery of an Unexplored Protein Structural Scaffold of Serine Protease from Big Blue Octopus (Octopus cyanea): A New Prospective Lead Molecule
Current Drug Discovery Technologies Hydrogen Sulfide: A New Tool to Design and Develop Drugs
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review
Current Neuropharmacology